AGC Inc. (5201.T)
Tokyo Stock Exchange: 5201 | Materials / Glass, Ceramics & Stone Products | ¥5,830 as of March 2026
Identity
| Item | Detail |
|---|---|
| Full legal name | AGC Inc. (formerly Asahi Glass Co., Ltd., renamed 2018) |
| Ticker / Exchange | 5201.T / Tokyo Stock Exchange, Prime Section |
| ADR | ASGLY (OTC) |
| GICS | Materials / Glass, Ceramics & Stone Products |
| Headquarters | Marunouchi, Chiyoda-ku, Tokyo, Japan |
| Founded | 1907 (incorporated 1950) |
| Employees | ~52,900 consolidated (~8,000 parent only) |
| Nikkei Index | Nikkei 225, Nikkei 300, Nikkei 500 |
| Website | agc.com |
| Credit ratings | R&I: AA / S&P: A- / Moody's: A2 |
Thesis
Conviction: Low-Medium | Target: ¥6,500-7,000 (~12-20% upside) | Sizing: 2-3% of portfolio
AGC is a cheap, well-run Japanese materials conglomerate trading at 0.83x book value with a 3.6% dividend yield and a 7.6% free cash flow yield. The market treats it as a boring glass company, and honestly, two-thirds of it is boring glass. But underneath the legacy businesses sits a portfolio of high-growth, high-barrier assets — display glass substrates (#2 globally), EUV mask blanks for semiconductors, fluorochemicals (#1 in ETFE), and biopharmaceutical CDMO services — that collectively represent ~27% of revenue and are growing 8-10% annually while the rest of the company grows at 3-4%.
The core question: can this portfolio transformation meaningfully lift ROE from ~5% toward 7-8%, or is AGC a perpetual value trap — decent cash flows, mediocre returns, a stock that never re-rates above book value?
Bull case
- Sum-of-parts discount is real. Value the semiconductor materials, fluorochemicals, and life science businesses at peer multiples (15-25x EBITDA) and the glass/commodity chemicals at 4-5x, and you get more than today's enterprise value. The conglomerate discount is excessive.
- FCF trajectory is genuinely improving. Free cash flow tripled from ¥33B (FY2023) to ¥96B (FY2025) even on flat revenue. Capex discipline is getting better.
- FY2026 guidance signals inflection. ¥150B operating income (+18% YoY) and ¥2.2T revenue (+7%) would be the first meaningful operating profit growth in three years.
- 3.6% dividend yield pays you to wait. Well-covered at 47% of FCF. Maintained through the FY2024 loss year. This is a real floor.
- Japan governance reform is a slow tailwind. Cross-shareholding unwinding could fund buybacks. TSE pressure for ROE improvement gives management external cover for bolder capital allocation.
Bear case
- Value trap. ROE stays at 5% forever because the high-growth segments are too small relative to the capital-hungry glass furnaces. The stock never re-rates.
- Energy costs are structural. Glass melting is extremely energy-intensive. A natural gas spike can erase 200-300bps of margin overnight.
- Corning keeps winning display substrates. Fusion-draw is structurally superior for Gen 10.5+ panels. AGC stays at #2 and the gap slowly widens.
- Hoya owns EUV mask blanks. AGC's #2 position at <30% share vs. Hoya's >70% means AGC is the backup supplier, not the leader. This caps the semiconductor materials upside.
- Conglomerate discount is permanent. Management will never spin off the good pieces. You are buying a basket, not a pure play.
Bottom line: This is a value play with income protection and optionality on portfolio transformation. Not a growth compounder. Not a turnaround. You buy it at 0.83x book, collect 3.6%, and wait. If ROE moves toward 7%, the stock re-rates to ¥7,000+ (1.0x book). If it doesn't, you at least got paid a decent yield on an investment-grade balance sheet. Best positioned as part of a barbell alongside Hoya (7741.T) for pure semiconductor substrate exposure.
Business
What they do
AGC is Japan's largest glass manufacturer and the world's most diversified glass and materials company. Founded in 1907 by the Iwasaki family (the Mitsubishi zaibatsu founders) to end Japan's dependence on imported sheet glass. Today it is a ¥2T revenue conglomerate operating across 30+ countries, organized around high-temperature processing expertise — whether melting glass at 1,500°C, producing fluorine-based chemicals, or manufacturing synthetic fused silica for semiconductor photomasks.
Think of AGC as the opposite of Hoya. Where Hoya is a precision-focused pure play that ruthlessly concentrates on high-margin niches, AGC is a sprawling materials platform that does a lot of things competently but nothing with the kind of dominant market position that commands premium multiples.
Segments
| Segment | What It Does | ~% of Revenue | Growth | Moat |
|---|---|---|---|---|
| Architectural Glass | Flat glass, low-e coated glass, fire-resistant glass — top 3 globally with Saint-Gobain and NSG | ~25% | Low single-digit, GDP-linked | Scale (float lines cost hundreds of millions) |
| Automotive | Windshields, tempered glass, HUD glass, glass antennas — top 3 globally | ~20% | 3-5% but higher on content-per-vehicle | Qualification cycles, oligopoly |
| Display (Electronics) | Glass substrates for TFT-LCD and OLED — #2 globally behind Corning (~20-25% share vs. Corning's ~50%) | ~10% | 3-5% (area demand) | 12-24 month customer qualification |
| Electronic Materials | EUV mask blanks (#2 behind Hoya), synthetic fused silica, CMP slurry, SiC jigs, IR filters | ~8% | 8-12% CAGR (secular) | Extreme technical barriers, decades of process know-how |
| Essential Chemicals | Chlor-alkali (caustic soda, PVC), urethane materials | ~15% | Cyclical | Integrated plants |
| Performance Chemicals | Fluoropolymers (Fluon ETFE — world #1), fluororubbers, fluorine gases, FORBLUE ion-exchange membranes | ~12% | 6-8% CAGR (EV + semi) | Technology IP, #1 share in ETFE |
| Life Science | CDMO via AGC Biologics — cell/gene therapy, antibodies, APIs (Copenhagen, Heidelberg, Seattle, Japan) | ~7% | 8-10% CAGR | GMP certification, multi-year contracts |
| Ceramics / Other | Refractories, fine ceramics, R&D services | ~3% | Stable | — |
How the technology works
The unifying thread is transforming raw silica sand into precision-engineered glass and chemical products:
-
Float glass (architectural/automotive): Molten glass is poured onto a bath of molten tin, where it floats and forms a perfectly flat ribbon. The tin bath gives surface flatness — like pouring syrup onto a still pool of water. Composition is soda-lime-silicate. Coatings (magnetron sputtering of thin metal oxide layers in a vacuum chamber) are where the margin premium lives.
-
Display glass substrates: Alkali-free borosilicate or aluminosilicate compositions — alkali metals would poison the thin-film transistors deposited on the surface. AGC uses an adapted float process. Corning uses its proprietary fusion-draw process (glass flows over a trough and meets at the bottom, creating two pristine surfaces that never touch a mold), which has structural advantages for Gen 10.5+ substrates.
-
Synthetic fused silica (semiconductor): Ultra-high-purity glass made by flame hydrolysis of silicon tetrachloride. Parts-per-billion impurity levels. Exceptional UV transparency for photomask blanks.
-
EUV mask blanks: The most demanding product. A fused silica substrate is polished to sub-angstrom flatness, then coated with ~40 alternating layers of molybdenum and silicon (Bragg reflector) that reflects ~67% of 13.5nm EUV light. Any single-particle defect can create a fatal flaw in the chip pattern. Each blank costs $50,000-100,000+.
Geographic mix
| Region | % of Revenue | Employees |
|---|---|---|
| Japan / Asia | ~64% | ~33,900 |
| Europe | ~28% | ~14,500 |
| Americas | ~8% | ~4,500 |
The European presence is a legacy of the 1981 Glaverbel acquisition (now AGC Glass Europe), which made AGC a dominant player in European architectural and automotive glass. ~200 subsidiaries worldwide.
Competitive position
| Competitor | Primary Overlap | Key Difference |
|---|---|---|
| Corning (GLW) | Display substrates (#1, ~50% share) | Fusion-draw technology moat; higher margins; more focused |
| Hoya (7741.T) | EUV mask blanks (#1, >70% share) | Pure-play precision optics; ~30% operating margins; dominant |
| Saint-Gobain (SGO.PA) | Architectural glass (#1 globally) | Larger building materials conglomerate; less electronics exposure |
| NSG/Pilkington (5202.T) | Architectural/automotive glass | Smaller, more leveraged, lower-margin |
| Fuyao Glass (3606.HK) | Automotive glass (#1 by volume) | Chinese cost leader; gaining share globally |
| **Nippon Electric Glass (5214/5214 | 5214.T)** | Display substrates (#3) |
Overall moat: Narrow. Strong in specific niches (Fluon ETFE is #1 globally — the purest moat in the portfolio), defensible in display substrates and mask blanks, but weak in commodity glass where pricing is competitive. The moat is a portfolio of barriers rather than a single dominant position.
TAM
- Global flat glass: ~$80B, 4-5% CAGR
- Display glass substrates: ~$10-12B, 3-5% CAGR
- Semiconductor materials: ~$70B+, with mask blanks >10% CAGR as EUV adoption accelerates
- Fluorochemicals: ~$30B+, growing with EV and semiconductor demand
- Biopharma CDMO: ~$20B+, 8-10% CAGR
AGC captures ~¥2T (~$13B) across $200B+ of addressable markets. Serviceable market is ~$30-40B, so penetration is 30-40%.
Industry cycle position
- Architectural glass: mid-cycle
- Automotive glass: mild downcycle (EV transition uncertainty)
- Display substrates: recovery (LCD downcycle bottomed in 2023, OLED investment accelerating)
- Semiconductor materials: structural uptrend (EUV still early innings; high-NA EUV just starting)
- Chemicals: mid-cycle
Value chain position
[Raw Materials: Silica Sand, Soda Ash, Fluorite]
→ [Glass/Chemical Manufacturing] ★ AGC
→ [Coated/Processed Glass, Display Substrates, Chemicals]
→ [Panel Makers, Automakers, Construction, Semiconductor Fabs]
→ [Consumer Electronics, Buildings, Vehicles, Chips]
Mid-value-chain materials manufacturer. Buys commodity inputs, transforms into engineered products. The materials layer captures a thin margin slice — a ¥100,000 display panel might have ¥2,000 of glass substrate content. AGC's 6% operating margins reflect this reality.
Management
Leadership
| Name | Title | Tenure | Background |
|---|---|---|---|
| Yoshinori Hirai | President & CEO | Since 2021 | Career AGC insider. Rose through the chemicals division. Architect of "AGC plus" portfolio transformation strategy. His chemicals background matters — Performance Chemicals is one of AGC's highest-margin segments. |
| Shinji Miyaji | Senior EVP | Current | Representative Director with broad operational responsibilities. Specific portfolio not disclosed in English IR — a transparency gap. |
| Hideyuki Kurata | EVP | Current | Representative Director. Another long-tenured executive with limited English-language disclosure. |
| Takuya Shimamura | Chairman | Since ~2021 | Hirai's predecessor as CEO. Sits on Nominating and Compensation committees. Active oversight role, not just ceremonial. |
Track record under Hirai: Navigated a challenging period — flat revenue (FY2023-2025), massive FY2024 extraordinary loss (likely Russian asset impairment), compressed margins. On the positive side: FCF tripled from ¥33B to ¥96B, dividend maintained through the loss year, FY2026 guidance represents first meaningful operating profit growth in three years.
Board quality
8 directors (4 internal, 4 independent = 50% independence). Meets 14 times annually. 1-year terms.
The independent directors are genuinely strong:
- Hiroyuki Yanagi — former CEO of Yamaha Motor (¥2.3T company), chairs both Nominating and Compensation committees. This is a real operator who can credibly challenge management.
- Isao Teshirogi — believed to be former pharma CEO; relevant domain expertise for the Life Science bet.
- Keiko Honda — finance and governance expertise.
- Koji Arima — industrial/technology background.
Separate Audit & Supervisory Board: 4 members (3 independent), met 14 times. Auditor: KPMG AZSA LLC (FY2024 fees: ¥259M). No qualifications or going-concern flags.
No poison pill. No dual-class shares. No staggered board. This company is exposed to market discipline.
Insider ownership & alignment
Here's the hard truth about Japanese insider ownership: it barely exists. Japanese executives get the vast majority of pay as salary and cash bonuses, with minimal equity. AGC's 7 internal directors shared ¥765M in total comp (~¥109M / ~$730K per director), plus ¥137M total in stock comp (~¥20M / ~$133K per director in equity). That's a rounding error for a ¥1.27T market cap company.
Stock compensation metrics are actually well-designed: ROE (30%), EBITDA (30%), relative TSR vs. TOPIX (20%), GHG intensity (10%), employee engagement (10%). The 50% weight on ROE + TSR is shareholder-friendly. Cash bonus is based on ROCE — which directly targets AGC's biggest weakness.
The alignment comes not from ownership but from career commitment. Hirai has spent his entire career at AGC. His reputation and legacy are tied to the company. That's a softer form of alignment than economic ownership, but it's real in the Japanese context.
SBC dilution is negligible — ¥137M for all directors combined is ~0.01% of market cap.
Capital allocation
| Category | Grade | Assessment |
|---|---|---|
| M&A | B | Disciplined but not aggressive. Glaverbel (1981) was transformative. AGC Biologics buildout is still proving itself. No large, conviction-driven deals. |
| Buybacks | C+ | Maintains flat share count (~217M) but not buying aggressively at 0.83x book. At below-book, buybacks are the highest-ROIC use of capital — and they're barely doing them. |
| Dividends | B | ¥210/share held since FY2021, including through FY2024 net loss. Reliable. But also flat for 5 years despite FCF tripling. Too conservative. |
| Capex | C | ¥180-196B annually on flat revenue. Payoff may come as life science and electronic materials capacity ramps, but no visible revenue growth yet. |
| Overall | C+ | Conservative and disciplined — won't blow up the balance sheet, won't dilute, won't overpay themselves. But also won't deploy capital aggressively toward highest-return opportunities. The ¥50B+ annual gap between FCF and dividends is not being used optimally. |
Shell & cross-holdings
Clean. ~200 subsidiaries are operating businesses, not shell structures. No related-party self-dealing, no nominee directors, no revenue circularity.
Cross-shareholdings (keiretsu legacy) represent "lazy capital" — if AGC holds ¥50-100B+ in cross-held equities, unwinding could fund meaningful buybacks. This is an opportunity, not a red flag.
Management verdict
| Dimension | Rating |
|---|---|
| Skin in the Game | Yellow — minimal ownership, standard for Japan |
| Shell / Cross-Holdings | Green — clean structure |
| Capital Allocation | Yellow — too passive at 0.83x book |
| Compensation | Green — low pay, well-designed metrics, negligible dilution |
| Governance | Green — genuine independence, strong committee chairs, no takeover defenses |
| Litigation | Green — clean record |
| Overall Grade | B- |
You can trust these people with your capital — you just may not see them work as hard as you'd like to grow it. Competent, honest, conservative. They act like stewards of a national institution rather than capital allocators trying to maximize shareholder returns.
Financials
Valuation snapshot (March 2026)
| Metric | Value |
|---|---|
| Market cap | ¥1.27T (~$8.5B) |
| Enterprise value | ~¥1.5T (~$10B) |
| P/E (TTM FY2025) | 18.3x |
| P/E (Forward FY2026E) | 16.1x |
| EV/EBITDA | ~5.5x |
| P/FCF (FY2025) | 13.2x |
| EV/Revenue | 0.73x |
| P/B (PBR) | 0.83x |
| FCF yield | 7.6% |
| Dividend yield | 3.60% |
| 52-week range | ¥3,870 – ¥6,959 |
Income statement (¥ Billions)
| Metric | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | 2,019 | 2,068 | 2,059 | 2,200 |
| Revenue growth | -0.8% | +2.4% | -0.4% | +6.9% |
| Operating income | 129 | 126 | 127 | 150 |
| Operating margin | 6.4% | 6.1% | 6.2% | 6.8% |
| Net income | 66 | (94) | 69 | 77 |
| Net margin | 3.3% | -4.5% | 3.4% | 3.5% |
| EPS (¥) | 305 | (443) | 326 | 363 |
FY2024 loss explained: Operating income was a healthy ¥126B. The net loss was driven by ~¥175B in extraordinary charges below the operating line — likely Russian asset impairments. The underlying business never deteriorated.
Cash flow & balance sheet (¥ Billions)
| Metric | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Operating cash flow | 213 | 285 | 274 | ~280 |
| Capex | ~180 | ~196 | ~178 | ~180 |
| Free cash flow | 33 | 89 | 96 | ~100 |
| FCF margin | 1.6% | 4.3% | 4.7% | ~4.5% |
| Total assets | 2,933 | 2,890 | 2,950 | — |
| Shareholders' equity | 1,447 | 1,436 | 1,485 | — |
| Equity ratio | 49.3% | 49.7% | 50.3% | — |
| Outstanding bonds | — | — | ¥180B | — |
| ROE | 4.6% | -6.5% | 4.7% | 5.2% |
| BPS (¥) | 6,832 | 6,774 | 7,004 | — |
The key story in the numbers: FCF tripled from ¥33B to ¥96B on essentially flat revenue. That is capex discipline working. The ¥210/share dividend costs ~¥45B, so there's ¥50B+ in annual FCF surplus after dividends — more than enough to fund growth or buybacks.
ROIC vs. WACC: ~5-6% ROIC against ~6-7% estimated WACC. Roughly breakeven on value creation. This is the core problem — AGC generates solid cash but the capital intensity means returns barely exceed cost of capital. The high-return segments aren't yet large enough to pull overall ROIC above WACC.
Quarterly incrementals (last 8 quarters)
| Quarter | Revenue (¥B) | Op. Income (¥B) | Op. Margin |
|---|---|---|---|
| Q1 FY2024 | 499 | 24 | 4.8% |
| Q2 FY2024 | 516 | 33 | 6.3% |
| Q3 FY2024 | 519 | 37 | 7.2% |
| Q4 FY2024 | 533 | 32 | 6.0% |
| Q1 FY2025 | 500 | 26 | 5.2% |
| Q2 FY2025 | 496 | 28 | 5.7% |
| Q3 FY2025 | 517 | 41 | 7.9% |
| Q4 FY2025 | 547 | 33 | 6.0% |
Q3 is consistently the strongest quarter (~7-8% margins). Q4 consistently decellerates to ~6% (year-end inventory adjustments, seasonal construction weakness). No hockey stick anywhere — margin improvement will be gradual, driven by mix shift, not a single inflection event.
Valuation vs. peers
| Company | EV/EBITDA | P/E (fwd) | P/B | FCF Yield | Div Yield |
|---|---|---|---|---|---|
| AGC (5201.T) | ~5.5x | 16.1x | 0.83x | 7.6% | 3.6% |
| Corning (GLW) | ~15x | 28x | 3.5x | 3% | 2.5% |
| Hoya (7741.T) | ~25x | 35x+ | 7x+ | 2.5% | 0.8% |
| NSG (5202.T) | ~5x | 8-10x | 0.5x | — | 2-3% |
| Saint-Gobain (SGO.PA) | ~7x | 12x | 1.5x | 5% | 3% |
The discounts to Corning and Hoya are justified — those companies have genuine technology moats and dramatically higher margins. AGC is in line with other diversified glass/materials peers. The 0.83x P/B says the market expects ROE to stay below cost of capital indefinitely.
What the market is pricing in
At ¥5,830, the market assumes: ~5% ROE forever, no portfolio transformation benefit, continued mid-single-digit margins, flat to low-single-digit growth. If AGC delivers FY2026 guidance, the stock is at 16x forward earnings with a 3.6% yield and 7.6% FCF yield on a clean upward trajectory — not expensive even without further growth.
Simple fair value
If ROE improves to 7% → P/B re-rates to ~1.0x → ¥7,004 fair value (~20% upside). If ROE stays at 5% → fair value is about current levels. At ¥6,400-6,700, margin of safety thins significantly. Entry discipline at ¥5,800 matters.
Ownership
| Holder | % Outstanding |
|---|---|
| Master Trust Bank of Japan (custodian) | 15.3% |
| Financial Institutions (total) | 31.9% |
| Foreign Investors | 24.5% |
| Individuals & Others | 30.1% |
| Other Corporations | 8.2% |
| Securities Firms | 5.3% |
Total shareholders: 121,563 (Dec 2025). Shares outstanding: 217.4M (treasury: ~5.07M). Margin sell balance (29,300) vs. margin buy balance (765,700) — net long speculative positioning. Covered by 9 analysts (BofA, Citi, CLSA, Daiwa, J.P. Morgan, Mizuho, Nomura, SBI, SMBC Nikko).
No dilution risk. No convertibles, warrants, or ATM programs. Funded by operating cash flow and straight bonds (¥180B outstanding, 0.31%-2.48% coupons, 2027-2036 maturities).
Catalysts & Risks
Secular tailwinds
| Tailwind | Mechanism | Durability |
|---|---|---|
| EUV / high-NA EUV adoption | More mask layers per chip + more fabs = more mask blanks and fused silica | 5-10yr+ |
| EV glass content per vehicle | Panoramic roofs, HUDs, glass antennas increase ASP from ~$200-300 to $500-800+ | 3-5yr |
| Green hydrogen | FORBLUE membranes for PEM electrolysis | 5-10yr+ (nascent) |
| Biopharma outsourcing | Cell/gene therapy CDMO demand at 8-10% CAGR | 5-10yr+ |
| Building energy efficiency | Green building codes drive coated glass adoption | 5-10yr+ |
| EV battery materials | Fluoropolymers (PVDF binders) in EV batteries | 3-5yr |
Near-term catalysts (0-12 months)
- Q1 FY2026 results (May 12, 2026): First test of ¥150B OI guidance. If Q1 tracks (~¥35B+), re-rating potential.
- Cross-shareholding unwinding: Proceeds could fund buybacks or special dividends.
- Japan governance reform pressure: TSE push for ROE improvement gives management cover for bolder capital allocation.
Medium-term catalysts (1-3 years)
- AGC Biologics utilization ramp (2027-2028): Swing from margin-dilutive to margin-accretive as new capacity fills.
- HUD windshield commercialization (2028): Independent HUD system could transform automotive segment margins.
- High-NA EUV transition: New-gen lithography creates window for AGC to improve its #2 mask blank position.
- OLED substrate share gains: Laptop/monitor OLED investment accelerating, particularly in China.
Key risks
| Risk | Likelihood | Impact | Mitigant |
|---|---|---|---|
| Value trap — ROE stays at 5% | High | High | "AGC plus" strategy; but requires 3-5yr execution |
| Energy cost inflation | High | Medium-High | Geographic diversification, furnace efficiency investment, hydrogen-fired furnaces under R&D |
| Display substrate share loss to Corning | Medium | Medium | Strong Asian customer relationships; focusing on OLED/specialty |
| Chinese glass substrate competition | Medium | Medium (3-5yr) | Technology/quality lead, but Chinese producers improving |
| Hoya's persistent EUV dominance | High | Medium | Caps semiconductor upside; AGC is the backup supplier, not the leader |
| Life Science execution risk | Medium | Medium | Growing market, multi-geography platform; closes as utilization hits 70-80% |
| Conglomerate discount persists | High | Medium | Unlikely to close without activist pressure or structural changes |
Emerging threats
- Chinese backward integration into display substrates: BOE and others exploring domestic glass production. 3-5 year horizon.
- Corning's Gen 10.5+ structural advantage: As industry standardizes on Gen 10.5 motherglass, Corning's fusion-draw moat grows.
- Samsung Corning Advanced Glass JV: Locks Corning into Samsung's substrate demand.
Downside scenario
Bear case (recession + energy spike + display downcycle): AGC revisits ¥4,500 (0.65x book, -23%). The 3.6% dividend provides partial protection, and the investment-grade balance sheet means zero solvency risk even in a downturn.
Thesis invalidation triggers
- FY2026 operating income materially misses guidance (<¥130B)
- Dividend cut
- ROE falls below 3% for two consecutive quarters
- Management abandons "AGC plus" portfolio transformation
Decision Log
Pre-buy checklist (March 15, 2026) — BUY (Scale In)
Entry price: ¥5,830 | Type: Undervalued asset + income
Pre-buy scorecard:
| Question | Answer |
|---|---|
| Can I state the thesis clearly? | Yes — undervalued conglomerate, hidden high-growth segments, 3.6% dividend floor |
| Do I understand the business? | Yes — glass, chemicals, electronic materials, CDMO |
| Are the financials healthy? | Yes — investment-grade balance sheet, improving FCF, well-covered dividend |
| Is the valuation reasonable? | Yes — 0.83x P/B, 5.5x EV/EBITDA, 7.6% FCF yield |
| Am I falling into a behavioral trap? | No — mild narrative seduction risk (the "cheap semiconductor play" story is more compelling than financial reality supports; electronic materials is only ~8% of revenue) |
| Do the technicals support buying now? | Mostly — 16% pullback from 52-week high, approaching 200-day MA, RSI ~30-40 |
| Have I sized appropriately? | Yes — 2-3% target, scaling in |
| Do I have a clear exit plan? | Yes |
Scaling plan:
- Tranche 1 (¥5,800-5,900): 40% of target position
- Tranche 2 (¥5,300-5,500): 30% at 200-day MA / prior support
- Tranche 3 (¥4,800-5,000): 30% only on broader market weakness
If stock reverses above ¥6,200 before tranche 2, accept partial position and don't chase.
Exit criteria:
- Success: ¥7,500+ (1.0x+ book, ~30% upside)
- Failure: Guidance miss, dividend cut, ROE <3% for two quarters
- Time stop: Flat below ¥6,500 after 2 years with no ROE improvement = value trap confirmed, exit
What would upgrade conviction to Medium-High:
- Q1 FY2026 operating income tracking to annual guidance
- Management announces enhanced capital return (larger buyback or dividend increase)
- AGC Biologics lands a major new CDMO contract
Key technical levels:
- Support: ¥5,500-5,600 (200-day MA, prior consolidation) → ¥5,000 (round number, prior resistance-turned-support)
- Resistance: ¥6,200-6,400 (early March trading zone) → ¥6,959 (52-week high)
- Stop-loss: ¥4,800
Next earnings: Q1 FY2026 results expected May 12, 2026.
Sources
- AGC Inc. Investor Relations: agc.com/en/ir/
- AGC Corporate Governance: agc.com/en/company/governance/
- AGC Stock Information & Dividend Data: agc.com/en/ir/stock/
- AGC IR Library — Presentations: agc.com/en/ir/library/briefing/
- Medium-term Management Plan: agc.com/en/ir/library/strategy/
- Yahoo Finance Japan: finance.yahoo.co.jp/quote/5201.T
- Kabutan: kabutan.jp/stock/finance?code=5201
- Nikkei: nikkei.com/nkd/company/?scode=5201
Topics
- ai-infrastructure
- optical-components
- supply-chain-security
- green-finance